New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
11:18 EDTINO, QLIK, INFN, CMG, DECK, CROX, MLNX, HLF, PBYI, CRUSOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI HLF MLNX CROX DECK CMG INFN QLIK CRUS
News For INO;PBYI;HLF;MLNX;CROX;DECK;CMG;INFN;QLIK;CRUS From The Last 14 Days
Check below for free stories on INO;PBYI;HLF;MLNX;CROX;DECK;CMG;INFN;QLIK;CRUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 23, 2014
11:19 EDTHLF Options with increasing implied volatility
Options with increasing implied volatility: HLF VRTX TRP CLX ETP VALE
10:21 EDTHLFHerbalife options active on wide price movement
Subscribe for More Information
09:13 EDTHLFOn The Fly: Pre-market Movers
Subscribe for More Information
06:29 EDTHLFHerbalife volatility increases on pullback
Subscribe for More Information
05:49 EDTCMG, HLFStocks with implied volatility movement; HLF CMG
Subscribe for More Information
September 22, 2014
18:18 EDTHLFOn The Fly: After Hours Movers
Subscribe for More Information
18:12 EDTHLFHerbalife reverses in after-hours trading, up 2.6%
16:17 EDTHLFIcahn has not sold any of Herbalife position, Gasparino says
Carl Icahn has not sold out of his stake in Herbalife, according to sources close to the matter, reported Fox Business' Charles Gasparino on Twitter.
15:54 EDTHLFHerbalife drop attributed to rumor of Icahn liquidating stake, Kass says
Subscribe for More Information
15:52 EDTHLFHerbalife volatility spikes on wide price movement
Subscribe for More Information
15:46 EDTHLFHerbalife drops over 13% to $38.90
Subscribe for More Information
08:10 EDTINOInovio initiates phase I clinical trial in patients with aerodigestive cancers
Inovio announced it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106. This immunotherapy targets human papillomavirus type 6, which causes most aerodigestive cancers. This study is part of Inovio's strategy to broadly expand clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause. It is a phase I, open label compassionate study enrolling patients with invasive cancer who have exhausted all other treatment options. The study will test Inovio's immunotherapy, INO-3106, alone or in combination with DNA-based IL-12, Inovio's proprietary immune activator, in subjects with HPV-6 associated aerodigestive malignancies. Successful results could open a path to pursuing an FDA orphan designation for aerodigestive cancers.
September 19, 2014
10:53 EDTINO Options with increasing implied volatility: ESI INO VALE AGNC
Subscribe for More Information
08:16 EDTINFNInfinera price target raised to $15 from $12 at MKM Partners
Subscribe for More Information
08:11 EDTCRUSTriQuint chip among those in iPhone 6 Plus, iFixit reports
Subscribe for More Information
08:03 EDTCRUSInvenSense, NXP, RF Micro chips included in iPhone 6, iFixit reports
Subscribe for More Information
07:10 EDTDECKDeckers Outdoor seeing strong growth across brands, says Piper Jaffray
Subscribe for More Information
September 17, 2014
10:00 EDTMLNXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:02 EDTQLIKQlik Technologies licensing growth poised to accelerate, says Pacific Crest
Subscribe for More Information
September 16, 2014
16:27 EDTMLNXMellanox initiated with a Neutral at Sterne Agee
Target $46.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use